Titouan Huppé
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Titouan Huppé has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alis Ilie
Université de Bourgogne Europe, Dijon, France
1 shared publication - Angélique Vienot
Department of medical oncology, University Hospital of Besançon, Besançon, France
1 shared publication - Anthony Bergeron
Centre Georges-François Leclerc
1 shared publication - Caroline Truntzer
Université Bourgogne Europe, Centre Georges-François Leclerc, Unicancer, Cancer Biology Transfer Platform, INSERM, CTM UMR 1231, TIRECs team
1 shared publication - Chloé Molimard
Department of Pathology, CHU Besançon, F-25000 Besançon, France
1 shared publication - Christophe Borg
Department of Medical Oncology, Centre Hospitalier Universitaire de Besançon, Besançon, France
1 shared publication
Latest Publications
- Open Access
- 2 December 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (12) , 2754
Deep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is a cancer with very poor prognosis despite early surgical management. To date, only clinical variables are used to predict outcome for decision-making about adjuvant therapy. We sought to generate a deep learning approach based on hematoxylin and eosin (H&E) or hematoxylin, eosin and saffron (HES) whole slides to predict patients’ outcome, compare these new entities with known molecular subtypes and question their biological significance; Methods: We used as a training set a retrospective private cohort of 206 patients treated by surgery for PDAC cancer and a validation cohort of 166 non-metastatic patients from The Cancer Genome Atlas (TCGA) PDAC project. We estimated a multi-instance learning survival model to predict relapse in the training set and evaluated its performance in the validation set. RNAseq and exome data from the TCGA PDAC database were used to describe the transcriptomic and genomic features associated with deep learning classification; Results: Based on the estimation of an attention-based multi-instance learning survival model, we identified two groups of patients with a distinct prognosis. There was a significant difference in progression-free survival (PFS) between these two groups in the training set (hazard ratio HR = 0.72 [0.54;0.96]; p = 0.03) and in the validation set (HR = 0.63 [0.42;0.94]; p = 0.01). Transcriptomic and genomic features revealed that the poor prognosis group was associated with a squamous phenotype. Conclusions: Our study demonstrates that deep learning could be used to predict PDAC prognosis and offer assistance in better choosing adjuvant treatment.
- 2 December 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (12) , 2754
Open AccessDeep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is a cancer with very poor prognosis despite early surgical management. To date, only clinical variables are used to predict outcome for decision-making about adjuvant therapy. We sought to generate a deep learning approach based on hematoxylin and eosin (H&E) or hematoxylin, eosin and saffron (HES) whole slides to predict patients’ outcome, compare these new entities with known molecular subtypes and question their biological significance; Methods: We used as a training set a retrospective private cohort of 206 patients treated by surgery for PDAC cancer and a validation cohort of 166 non-metastatic patients from The Cancer Genome Atlas (TCGA) PDAC project. We estimated a multi-instance learning survival model to predict relapse in the training set and evaluated its performance in the validation set. RNAseq and exome data from the TCGA PDAC database were used to describe the transcriptomic and genomic features associated with deep learning classification; Results: Based on the estimation of an attention-based multi-instance learning survival model, we identified two groups of patients with a distinct prognosis. There was a significant difference in progression-free survival (PFS) between these two groups in the training set (hazard ratio HR = 0.72 [0.54;0.96]; p = 0.03) and in the validation set (HR = 0.63 [0.42;0.94]; p = 0.01). Transcriptomic and genomic features revealed that the poor prognosis group was associated with a squamous phenotype. Conclusions: Our study demonstrates that deep learning could be used to predict PDAC prognosis and offer assistance in better choosing adjuvant treatment.